Illumina, Inc. (NASDAQ:ILMN) and Bio-Rad Laboratories, Inc.
(NYSE:BIO) (NYSE:BIOb) today announced the launch of the Illumina®
Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan
Healthcare Conference. The comprehensive solution is the first
next-generation sequencing (NGS) workflow for single-cell analysis,
providing researchers the ability to investigate the coordinated
contribution of individual cells in tissue function, disease
progression, and therapeutic response.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170109006365/en/
Illumina® Bio-Rad® Single-Cell Sequencing
Solution, including new ddSEQ Single-Cell Isolator (pictured with
NextSeq 500) (Photo: Business Wire)
Single-cell analysis enables a deep view into the gene
expression of individual cells to understand their functions in
complex tissues. The solution delivers high-throughput sequencing
of thousands of individual cells, traditionally a challenging,
costly, and time consuming process. Human development and disease
research, fields in which single-cell sequencing is widely
applicable, is expected to benefit most from this new offering.
“Single-cell genomics provides the opportunity to look at stem
cells turning into neurons that are lost in diseases like
Parkinson’s and amyotrophic lateral sclerosis (also known as Lou
Gehrig’s disease) with much higher accuracy,” said Clive Svendsen,
PhD, Director, Cedars-Sinai Board of Governors Regenerative
Medicine Institute in Los Angeles. His laboratory tested the
application of the new platform to profile single cells used in
modeling neurodegenerative diseases.
“Using the solution made it possible to detect single cells in a
population that was maturing faster than others, allowing us to
produce better models of disease,” added Ritchie Ho, PhD, Project
Scientist in the Cedars-Sinai Board of Governors Regenerative
Medicine Institute and lead researcher for the testing.
The solution comprises the ddSEQ™ Single-Cell Isolator and
SureCell™ WTA 3’ Library Prep Kit. Bio-Rad’s best-in-class droplet
partitioning technology, Droplet Digital™ technology, is used to
isolate and barcode single cells for downstream sequencing on many
of Illumina’s leading NGS instruments. The comprehensive workflow
solution includes primary and secondary data analysis conducted via
the BaseSpace® Informatics Suite, Illumina’s cloud-based genomics
computing environment, and tertiary data analysis and visualization
with SeqGeq™ from FlowJo, LLC, the market leader in flow cytometry
analysis.
“Through our close collaboration with Illumina we developed a
seamless and scalable solution for single-cell analysis,” said
Annette Tumolo, Bio-Rad Executive Vice President and General
Manager, Digital Biology Group. “We are proud to equip cell
biologists and others in the research community with the tools they
need to power new discovery.”
“By offering cell biologists access to technologies that make
single-cell analysis cost effective and easy to adopt, we hope to
enable scientists to advance complex disease research using gene
expression insights,” said Rob Brainin, Vice President and General
Manager, Applied Genomics at Illumina. “Our collaboration with
Bio-Rad has allowed us to bring this technology to market quickly
and empower our customers to unlock the power of the genome to
improve human health.”
The Illumina® Bio-Rad® Single-Cell Sequencing Solution will
begin shipping in early February. For more information about the
instruments, reagents, and workflow, visit
www.bio-rad.com/ddSEQ.
For Research Use Only. Not for use in diagnostic
procedures.
About Illumina
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical and applied markets.
Our products are used for applications in the life sciences,
oncology, reproductive health, agriculture, and other emerging
segments. To learn more, visit www.illumina.com and
follow @illumina.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) (BIOb) develops,
manufactures, and markets a broad range of innovative products and
solutions for the life science research and clinical diagnostic
markets. The company is renowned for its commitment to quality and
customer service among university and research institutions,
hospitals, public health and commercial laboratories, as well as
the biotechnology, pharmaceutical, and food safety industries.
Founded in 1952, Bio-Rad is based in Hercules, California, and
serves more than 100,000 research and healthcare industry customers
through its global network of operations. The company employs more
than 8,000 people worldwide and had revenues exceeding $2 billion
in 2015. For more information, please visit www.bio-rad.com.
Illumina Forward-Looking Statements
This release contains forward-looking statements that involve
risks and uncertainties, such as Illumina’s expectations regarding
the launch of any products. Among the important factors that could
cause actual results to differ materially from those in any
forward-looking statements are (i) our ability to further develop
and commercialize our instruments and consumables and to deploy new
products, services, and applications, and expand the markets, for
our technology platforms; (ii) our ability to manufacture robust
instrumentation and consumables; (iii) achievement and timing of
the planned deconsolidation of GRAIL, Inc.’s financial results in
our financial statements; (iv) our ability to successfully identify
and integrate acquired technologies, products, or businesses; (v)
our expectations and beliefs regarding future conduct and growth of
the business and the markets in which we operate; (vi) challenges
inherent in developing, manufacturing, and launching new products
and services; and (vii) the application of generally accepted
accounting principles, which are highly complex and involve many
subjective assumptions, estimates, and judgments, together with
other factors detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We
undertake no obligation, and do not intend, to update these
forward-looking statements, to review or confirm analysts’
expectations, or to provide interim reports or updates on the
progress of the current quarter.
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding plans to introduce
new products and the opportunities that may result from such new
products. Forward-looking statements generally can be identified by
the use of forward-looking terminology such as “plan”, “believe,”
“expect,” “anticipate,” “may,” “will,” “intend,” “estimate,”
“continue,” or similar expressions or the negative of those terms
or expressions, although not all forward-looking statements contain
these words. Such statements involve risks and uncertainties, which
could cause actual results to vary materially from those expressed
in or indicated by the forward-looking statements. These risks and
uncertainties include our ability to develop and market new or
improved products, our ability to compete effectively,
international legal and regulatory risks, and product quality and
liability issues. For further information regarding our risks and
uncertainties, please refer to the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operation” in Bio-Rad’s public reports filed with the Securities
and Exchange Commission, including our most recent Annual Report on
Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions
you not to place undue reliance on forward-looking statements,
which reflect an analysis only and speak only as of the date
hereof. We disclaim any obligation to update these forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170109006365/en/
Bio-Rad Laboratories, Inc.Tina Cuccia, Corporate
Communications510-724-7000tina_cuccia@bio-rad.comorIllumina,
Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Gwen
Gordon858-882-6822pr@illumina.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Sep 2023 to Sep 2024